Apellis Pharmaceuticals, Inc. - APLS

Ownership (Schedule 13D / 13G) · latest 50 filings · Back to all files
Visible: 0
Filed Form Reporting person Percent Shares SEC
Jun 05, 2026 SCHEDULE 13G/A Morgan Stanley 0.0% 0 View
Jun 05, 2026 SCHEDULE 13G/A Morgan Stanley Capital Services LLC 0.0% 0 View
May 15, 2026 SCHEDULE 13G/A RTW Investments, LP 2.9% 3,685,045 View
May 15, 2026 SCHEDULE 13G/A Roderick Wong 2.9% 3,685,045 View
May 15, 2026 SCHEDULE 13G/A Deep Track Capital, LP 3.55% 4,532,374 View
May 15, 2026 SCHEDULE 13G/A Deep Track Biotechnology Master Fund, Ltd. 3.55% 4,532,374 View
May 15, 2026 SCHEDULE 13G/A David Kroin 3.55% 4,532,374 View
May 14, 2026 SCHEDULE 13D/A View
Apr 07, 2026 SCHEDULE 13G/A Wellington Management Group LLP 0.2% 249,635 View
Apr 07, 2026 SCHEDULE 13G/A Wellington Group Holdings LLP 0.2% 249,635 View
Apr 07, 2026 SCHEDULE 13G/A Wellington Investment Advisors Holdings LLP 0.2% 249,635 View
Mar 26, 2026 SCHEDULE 13G/A The Vanguard Group 0.0% 0 View
Feb 17, 2026 SCHEDULE 13G RTW Investments, LP 6.1% 7,666,764 View
Feb 17, 2026 SCHEDULE 13G Roderick Wong 6.1% 7,666,764 View
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G. Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F). Amendments (/A) can repeat the same holder over time, so rows should not be summed. Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.